World Health Organization recommendations for the influenza virus vaccine composition for the 2020 southern hemisphere season
On September 2019, WHO has agreed on the recommended composition of the quadrivalent and trivalent influenza vaccines for the southern hemisphere 2020 influenza season.
WHO recommendations for influenza virus vaccine composition for the 2019–2020 northern hemisphere season
On 18–20 February 2019, the World Health Organization (WHO) agreed on the recommended composition of the quadrivalent influenza vaccine for the northern hemisphere 2019–2020 influenza season: an A/Brisbane/02/2018 (H1N1)pdm09-like virus, an A(H3N2) virus component to be announced on 21 March 2019, a B/Colorado/06/2017-like virus (B/Victoria/2/87 lineage) and a B/Phuket/3073/2013-like virus (B/Yamagata/16/88 lineage).
WHO recommendations for influenza virus vaccine composition for the 2018-2019 Northern hemisphere season
On 19-21 February 2018 the World Health Organization (WHO) agreed on the recommended composition of the trivalent influenza vaccine for the northern hemisphere 2018-2019 influenza season.
WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.
WHO recommendations for influenza virus vaccine composition for the 2016 southern hemisphere season
The WHO recommendations reflect the currently circulating viruses in the southern hemisphere, and the change of both A(H3N2) and B virus components is based on the available surveillance and virus characterisation data.
Universal influenza vaccine candidates provide heterosubtypic protection in mice, ferrets and non-human primates
The results from three animal species all point in the same direction: it seems possible to develop influenza vaccine candidates with at least broader cross-protection and possibly universal ones using different technologies.
Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2
This new publication from Novartis in collaboration with public health and academic researchers in Finland and the US adds to the evidence-base on how narcolepsy might have been triggered in genetically susceptible individuals.
Council of the European Union conclusions on vaccination
ECDC welcomes the Council Conclusions, as of 1 December 2014, and will continue to support the EU and its Member States in responding to the invitations for action described in these and previous Council conclusions.
Update on narcolepsy cases associated with Pandemrix vaccination in 2009 in the Netherlands
In November 2014, the Pharmacovigilance Centre of Netherlands (Lareb) provided an updated overview of Dutch cases of narcolepsy reported to have a link to Pandemrix.